证券代码：300534 证券简称：陇神戎发 公告编号：2025-081 甘肃陇神戎发药业股份有限公司 关于续聘 2025 年度会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 本次续聘会计师事务所符合财政部、国务院国资委、证监会印发的《国有企 业、上市公司选聘会计师事务所管理办法》（财会〔2023〕4 号）的规定。 甘肃陇神戎发药业股份有限公司（以下简称"公司"或"陇神戎发"）于 2025 年 12 月 3 日召开第五届董事会第二十五次会议，审议通过《关于续聘 2025 年度会计师事务所的议案》，决定续聘希格玛会计师事务所（特殊普通合伙）（以 下简称"希格玛会计师事务所"）为公司 2025 年度审计机构，该议案尚需提交 公司股东会审议。现将相关情况公告如下： 一、拟续聘会计师事务所的基本情况 （一）机构信息 1.基本信息 业务资质：1994 年获得财政部、中国证券监督管理委员会核发的《会计师 事务所证券、期货相关业务许可证》，是我国最早从事证券服务业务的会计师事 务所之一。 人员信息：2024 年末合伙人 61 名、注册会计师 2 ...

证券代码：300534 证券简称：陇神戎发 公告编号：2025-082 甘肃陇神戎发药业股份有限公司 6.会议的股权登记日：2025年12月12日 关于召开2025年第六次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1.股东会届次：2025年第六次临时股东会 2.股东会的召集人：董事会 3.本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所 创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号—创业板上 市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》的 有关规定。 4.会议时间： （1）现场会议时间：2025年12月19日14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025年12月19日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互 联网投票系统投票的具体时间为2025年12月19日9:15至15:00的任意时间。 5.会议的召开方式：现场表决与网络投票相结合。 7.出席对象： （1）截至202 ...

一、董事会会议召开情况 证券代码：300534 证券简称：陇神戎发 公告编号：2025-080 甘肃陇神戎发药业股份有限公司 第五届董事会第二十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 甘肃陇神戎发药业股份有限公司（以下简称"公司"）第五届董事会第二十 五次会议通知于 2025 年 11 月 30 日以电子邮件等方式发出，会议于 2025 年 12 月 3 日以通讯方式召开。本次会议由公司董事长康永红先生主持，应出席会议董 事 9 人，实际出席会议董事 9 人，公司高级管理人员列席了会议。本次会议的召 集、召开符合《公司法》等有关法律、行政法规、部门规章和《公司章程》的相 关规定，合法有效。 二、董事会会议审议情况 会议审议并通过了如下议案： 1.审议通过《关于续聘 2025 年度会计师事务所的议案》 经审议，董事会同意公司续聘希格玛会计师事务所（特殊普通合伙）为公司 2025 年度财务审计机构和内控审计机构。2025 年度审计费用为 53.00 万元（含 税），其中：财务审计费用 43.00 万元（含税），内部控制审计费用 10.00 ...

Core Viewpoint - Longshen Rongfa's stock price has shown a significant increase this year, with a notable rise in trading volume and market capitalization, indicating positive investor sentiment and potential growth in the pharmaceutical sector [1][2]. Group 1: Stock Performance - As of December 3, Longshen Rongfa's stock price increased by 2.18% to 10.79 CNY per share, with a trading volume of 1.77 billion CNY and a turnover rate of 5.49%, resulting in a total market capitalization of 32.73 billion CNY [1]. - The stock has risen by 24.60% year-to-date, with a 3.06% increase over the last five trading days, 5.89% over the last 20 days, and 6.10% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Longshen Rongfa reported a revenue of 647 million CNY, a year-on-year decrease of 19.71%, while the net profit attributable to shareholders was 27.03 million CNY, reflecting a year-on-year growth of 9.13% [2]. - Cumulatively, the company has distributed dividends amounting to 42.64 million CNY since its A-share listing, with 24.27 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of November 28, the number of shareholders for Longshen Rongfa reached 27,800, an increase of 3.93% from the previous period, with an average of 10,874 circulating shares per shareholder, a decrease of 3.78% [2]. - Among the top ten circulating shareholders, Huatai-PineBridge's Zhongzheng Traditional Chinese Medicine ETF holds 1.33 million shares, an increase of 351,800 shares compared to the previous period [3].

Core Viewpoint - The company, Longshen Rongfa, announced that it received a medical device registration certificate from the National Medical Products Administration of China for its blood dialysis concentrate solution on November 28, 2025 [2] Group 1 - The product name is blood dialysis concentrate solution [2] - The registration certificate was issued by the National Medical Products Administration of China [2] - The announcement was made on the evening of November 28 [2]

Group 1 - The Chinese medicine sector experienced a decline of 0.83% on November 28, with Yue Wannianqing leading the drop [1] - The Shanghai Composite Index closed at 3888.6, up 0.34%, while the Shenzhen Component Index closed at 12984.08, up 0.85% [1] - Key stocks in the Chinese medicine sector showed mixed performance, with Tai Long Pharmaceutical rising by 5.37% to a closing price of 8.04 [1] Group 2 - Yue Wannianqing saw a significant drop of 13.71%, closing at 22.84, with a trading volume of 296,100 shares [2] - Other notable declines included Zhongsheng Pharmaceutical, which fell by 10.00% to 23.95, and Te Yi Pharmaceutical, which decreased by 6.41% to 14.01 [2] - The overall net capital flow in the Chinese medicine sector indicated a net outflow of 981 million yuan from main funds, while retail investors contributed a net inflow of 766 million yuan [2]

Group 1 - The core point of the article is that Longshen Rongfa has received a medical device registration certificate for its "blood dialysis concentrate" from the National Medical Products Administration of China, effective November 28, 2025 [1] - Longshen Rongfa's revenue composition for the first half of 2025 shows that pharmaceutical sales account for 86.53%, medical device sales for 6.69%, logistics distribution for 4.48%, property leasing for 0.76%, and consulting services for 0.7% [1] - As of the report date, Longshen Rongfa has a market capitalization of 3.1 billion yuan [1]

Core Viewpoint - The company, Longshen Rongfa, has received a medical device registration certificate for its blood dialysis concentrate solution from the National Medical Products Administration, indicating a significant regulatory milestone for the company in the healthcare sector [1] Group 1: Product Details - The blood dialysis concentrate solution consists of two parts: A concentrate and B concentrate [1] - A concentrate includes sodium chloride (NaCl), potassium chloride (KCl), calcium chloride (CaCl2·2H2O), magnesium chloride (MgCl2·6H2O), acetic acid (CH3COOH), and dialysis water [1] - B concentrate is composed of sodium bicarbonate (NaHCO3) and dialysis water [1] Group 2: Application Scope - The product is intended for use in the treatment of acute renal failure and chronic renal failure through blood dialysis [1]

Core Viewpoint - The company, Longshen Rongfa, has received a medical device registration certificate for its blood dialysis concentrate from the National Medical Products Administration, indicating a significant regulatory milestone for its product line [1] Group 1: Product Details - The blood dialysis concentrate consists of two parts: A concentrate and B concentrate [1] - A concentrate includes sodium chloride (NaCl), potassium chloride (KCl), calcium chloride (CaCl2.2H2O), magnesium chloride (MgCl2.6H2O), acetic acid (CH3COOH), and dialysis water [1] - B concentrate is composed of sodium bicarbonate (NaHCO3) and dialysis water [1] Group 2: Application Scope - The product is intended for use in the treatment of acute renal failure and chronic renal failure through blood dialysis [1]

证券代码：300534 证券简称：陇神戎发 公告编号：2025-079 甘肃陇神戎发药业股份有限公司 关于获得血液透析浓缩液医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 注册人名称：甘肃陇神戎发药业股份有限公司 注册人住所及生产地址：甘肃省兰州市榆中县定远镇国防路 10 号 产品名称：血液透析浓缩液 型号、规格： | 型号 | 组成 | 规格 | 装量 | | --- | --- | --- | --- | | LS-Y1 | A 浓缩液 | A1 | 5L | | | | A2 | 10L | | | B 浓缩液 | B1 | 6L | | | | B2 | 12L | 结构及组成：血液透析浓缩液由 A 浓缩液和 B 浓缩液两部分组成。A 浓缩液 由氯化钠（NaCl）、氯化钾（KCl）、氯化钙（CaCl2·2H2O）、氯化镁（MgCl2·6H2O）、 冰醋酸（CH3COOH）及透析用水组成，B 浓缩液由碳酸氢钠（NaHCO3）和透析用 水组成。 适用范围：用于急性肾衰竭、慢性肾衰竭的血液透析治疗。 生效日期：二〇二五年十一月二十八日 ...